Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients-Reference-Cited by-同舟云学术

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

Published:2021-06 Issue:3 Volume:2 Page:520-524
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Chevallier Patrice¹²^ORCID,Coste‐Burel Marianne³,Le Bourgeois Amandine¹,Peterlin Pierre¹,Garnier Alice¹,Béné Marie C.²⁴,Imbert Berthe‐Marie³,Drumel Thomas³,Le Gouill Steven¹,Moreau Philippe¹,Mahe Beatrice¹,Dubruille Viviane¹,Blin Nicolas¹,Lok Anne¹,Touzeau Cyrille¹^ORCID,Gastinne Thomas¹,Jullien Maxime¹,Vanthygem Sophie¹,Guillaume Thierry¹²

Affiliation:

1. Department of Hematology Nantes University Hospital Nantes France

2. INSERM UMR1232 CRCINA IRS‐UN University of Nantes Nantes France

3. Department of Virology Nantes University Hospital Nantes France

4. Department of Hematology Biology Nantes University Hospital Nantes France

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.242

Reference13 articles.

1. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

2. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience